Effect of NMDA receptor antagonists on behavioral impairment induced by chronic treatment with dexamethasone.

Journal Title: Pharmacological Reports - Year 2005, Vol 57, Issue 1

Abstract

Severe and prolonged stress but also long-term treatment with glucocorticoids (GCs) have been described to cause brain damage (especially hippocampal and striatal neurons) in humans as well as in animals. GCs potentiate stress or ischemia-induced accumulation of excitatory amino acids (EAA) in the extracellular space of the hippocampus. It was shown that EAA play a major role in various neurologic disorders with cognitive dysfunction. Many authors suggested the neuroprotective effect of N-methyl-D-aspartate (NMDA) glutamate receptor antagonists in some acute or chronic neurodegenerative diseases. On the other hand, many NMDAreceptor antagonists produce highly undesirable side-effects at the doses within their putative therapeutic range. The aim of the present study was to evaluate the behavioral effects (memory performance, motor coordination, lethality and body weight) of MK-801 or memantine (MEMAN, non-competitive NMDAreceptor antagonists) (at the doses of 25 and 50 microg/kg/day or 2.5 and 5.0 mg/kg/day, respectively) on neurotoxicity induced by dexamethasone (DEX) administered chronically at the doses of 40 or 80 mg/kg/day in mice. It was shown that prolonged treatment (for 10 days) with DEX at the dose of 80 mg/kg/day (but not at 40 mg/kg/day) significantly decreased the retention time in the memory task in mice and impaired the motor coordination in "chimney" test. Neither MK-801 nor MEMAN (at the both doses used) were able to counteract the behavioral impairment induced by DEX administration. Moreover, the potentiation of the body weight reduction and lethality induced by DEX were noted in mice co-treated with MK-801 or MEMAN. The above findings suggest that MK-801 or MEMAN at the doses used have no neuroprotective effect. On the contrary, both NMDA receptor antagonists potentiate the toxicity of DEX given chronically.

Authors and Affiliations

Zofia Danilczuk, Grażyna Ossowska, Tomasz Łupina, Katarzyna Cieślik, Iwona Żebrowska-Łupina

Keywords

Related Articles

Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice.

The aim of this study was to evaluate the effects of H(1) (antazoline and astemizole) or H(2) (cimetidine and famotidine) histamine receptor antagonists on the clonic phase, tonic seizures and morality of mice challenged...

Involvement of prolactin and somatostatin in depression and the mechanism of action of antidepressant drugs.

Neuropeptides have been implicated in the physiology and pathophysiology of stress responses and therefore may play an important role in the pathogenesis of affective disorders such as Major Depression Disorder (MDD). Th...

Urocortin: a protective peptide that targets both the myocardium and vasculature.

The urocortins are a family of endogenously produced peptide hormones that show great promise as potential drugs for the treatment of heart disease. They can increase contractility and cardiac output without causing chan...

Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients.

Digoxin, a drug of narrow therapeutic index, is a substrate for common transmembrane transporter, P-glycoprotein, encoded by ABCB1 (MDR1) gene. It has been suggested that ABCB1 polymorphism, as well as co-administration...

Altered response of human umbilical artery to 5-HT in gestational diabetic pregnancy.

The aim of this investigation was to evaluate serotonin (5-HT) action on isolated human umbilical arteries (HUA) from normal and gestational diabetes mellitus (GDM) pregnancies. 5-HT caused HUA contraction in a concentra...

Download PDF file
  • EP ID EP82260
  • DOI -
  • Views 117
  • Downloads 0

How To Cite

Zofia Danilczuk, Grażyna Ossowska, Tomasz Łupina, Katarzyna Cieślik, Iwona Żebrowska-Łupina (2005). Effect of NMDA receptor antagonists on behavioral impairment induced by chronic treatment with dexamethasone.. Pharmacological Reports, 57(1), 47-54. https://europub.co.uk/articles/-A-82260